Author Archives: admin

Covid-19 impact on Global Stem Cell Therapy Market by Manufactures, Size, Share, Driving Factors, Sales and Forecast 2020-2025|Osiris Therapeutics,…

By adminJuly 22, 2020Stell Cell Research

The global Stem Cell Therapy Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Stem Cell Therapy Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Stem Cell Therapy Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Stem Cell Therapy Market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Stem Cell Therapy Market.

Leading players of the global Stem Cell Therapy Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Stem Cell Therapy Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Stem Cell Therapy Market. It also provides useful recommendations for new as well as established players of the global Stem Cell Therapy Market.

Final Stem Cell Therapy Report will add the analysis of the impact of COVID-19 on this Market.

Stem Cell Therapy Market competition by top manufacturers/Key player Profiled: Osiris Therapeutics,NuVasive,Chiesi Pharmaceuticals,JCRPharmaceutical,Pharmicell,Medi-post,Anterogen,Molmed,Takeda (TiGenix)

>>> Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Stem Cell Therapy Market:

The global Stem Cell Therapy market was valued at $XX million in 2018, and MAResearch analysts predict the global market size will reach $XX million by the end of 2028, growing at a CAGR of XX% between 2018 and 2028.

This report provides detailed historical analysis of global market for Stem Cell Therapy from 2013-2018, and provides extensive market forecasts from 2020-2028 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Stem Cell Therapy market.

Segmentation by Product:

Autologous Allogeneic

Segmentation by Application:

Musculoskeletal Disorder Wounds & Injuries Cornea Cardiovascular Diseases Others

Competitive Analysis:

Global Stem Cell Therapy Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Stem Cell Therapy Market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Scope of the Report: The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Stem Cell Therapy Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

The report offers in-depth assessment of the growth and other aspects of the Stem Cell Therapy market in important countries (regions), including:

North America(United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

For Customised Template PDF Report: https://www.reporthive.com/request_customization/2162381

Table of Contents

Report Overview:It includes major players of the global Stem Cell Therapy Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Stem Cell Therapy Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Stem Cell Therapy Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Stem Cell Therapy Market by application, it gives a study on the consumption in the global Stem Cell Therapy Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Stem Cell Therapy Market are profiled in this section. The analysts have provided information about their recent developments in the global Stem Cell Therapy Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Stem Cell Therapy Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Stem Cell Therapy Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Stem Cell Therapy Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us: Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Follow this link:
Covid-19 impact on Global Stem Cell Therapy Market by Manufactures, Size, Share, Driving Factors, Sales and Forecast 2020-2025|Osiris Therapeutics,...

Stem Cell And Regenerative Therapy Market Monisizering Growth Opportunities COVID-19 2024 – 3rd Watch News

By adminJuly 22, 2020Embryonic Stem Cells

he global stem cell and regenerative medicines market should grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11723

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

More Info of Impact [emailprotected]https://www.trendsmarketresearch.com/report/covid-19-analysis/11723

Originally posted here:
Stem Cell And Regenerative Therapy Market Monisizering Growth Opportunities COVID-19 2024 - 3rd Watch News

Seer raises another $55M and finally reveals proteomic tech can it hold up? – Endpoints News

By adminJuly 22, 2020Stem Cell Clinic

Two years ago, Omid Farokhzad left his prominent nano-medicine lab at Bostons Brigham and Womens Hospital and moved across the country to found a startup off technology that, he said, could change the field of proteomics and, with it, parts of medicine, agriculture and a range of fields.

Today, Farokhzad has finally revealed what that technology is. In aNature Communicationspaper, he showed how his company, Seer, and their lead product, called the Proteograph, can use nanoparticles to analyze the protein compositions in a single blood sample, like a fishing net webbing the contents of a particular swath of sea. Or to use the companys preferred metaphor like a sequencing machine reading out the base pairs on a particular strand of DNA.

Alongside the publication, Seer also announced a new $55 million round to help launch the product, bringing its total financing to over $150 million.

We now enable what was previously not possible, Farokhzad toldEndpoints News.Today about every 25 seconds, someone [can] sequence anothers human genome. This technology allows you to begin to interrogate the human proteome in an unbiased way, deep, in speed and scale.

Its a bold talk for a field full of it, although its now at least burnished by peer-reviewed data something that cannot be said for all of Seers competitors. The proteome has long been a source of fascination for scientists, for the simple fact that were built of proteins, and changes in the concentration or shape of proteins are what ultimately underlie changes in function and disease.

The problem is that its far harder to get a complete picture of someones proteins than it is of their genes. Genes are comparatively simple: 4 base pairs, each of which can only bind in one direction. Proteins can be made of up to 20 amino acids that bind in myriad ways. They can also change after translation. The technological or computing power simply did not exist to analyze all of them at a rate comparable to how researchers can analyze genes.

Thats changed to a degree in recent years. Several companies have popped up, most notably SomaLogic, offering to screen peoples blood for a limited set of proteins data have indicated correlates with disease. Researchers also have techniques to map out every protein in a blood sample, but it can take months.

Seer claims to be able to do screening in a fast and unbiased way, similar to how we can now analyze genes a quick and complete picture. A new company, called Nautlius, launched this year with over $100 million from prominent tech funds with a similar promise, but they are earlier stage and have yet to disclose their tech. And everyone is comparing themselves to Illumina, the $60 billion sequencing giant, which itself has a proteomics division.

The key variable that next-gen sequencing and in particular that Illumina technology changed was the ability to access the genome or the transcriptome in an unbiased, deep way, rapidly and at scale, Omead Ostadan, a former Illumina executive who was recently named Seers COO and president, told Endpoints. With Seers proteomics tech, you enable enormous depth and breadth analogous to the biologic insight that emerged when you could [first] access genomic information.

Seer has developed over 250 nanoparticles for its Proteograph. These different particles, when put in the blood, attract different proteins that bond to chemical groups on the surface, forming a corona, or a kind of molecular halo around the protein. Other proteins then bind to those proteins and so on. Not every nanoparticle will bind to every protein, but if you put in enough, the different coronas will give a kind of picture both of what proteins exist and if those proteins have changed shape.

As a proof of concept, the company looked at samples from early-stage non-small cell lung cancer patients and found proteins that correlated with disease.

This kind of analysis, Farokhzad said, could be used to diagnose patients early a goal shared by well-backed liquid biopsy companies like GRAIL and Karius. It could also, he said, be used to find new proteins associated with cancer, and those proteins could then become biomarkers or targets for new therapies. There are also applications in agriculture and environmental science.

For now, the company is focused on building new nanoparticles and launching the product next year, before finding new applications. Theyll have to seal partners and buyers, who in turn will be able to say if the product is just as transformational as they claim.

It sounds simple, but having lived through product development and commercialization, theres a lot to do, Ostadan said.

Stem Cell Alopecia Treatment Market Segmentation By Qualitative And Quantitative Research Incorporating Impact Of Economic and Non-Economic Aspects By…

By adminJuly 22, 2020Stem Cell Treatment

New Jersey, United States,- The recent report on Stem Cell Alopecia Treatment Market offered by Verified Market Research, comprises of a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. Additionally, the report also highlights the challenges impeding market growth and expansion strategies employed by leading companies in the Stem Cell Alopecia Treatment market.

This is the most recent report inclusive of the COVID-19 effects on the functioning of the market. It is well known that some changes, for the worse, were administered by the pandemic on all industries. The current scenario of the business sector and pandemics impact on the past and future of the industry are covered in this report.

In market segmentation by manufacturers, the report covers the following companies-

Exploring the growth rate over a period

Business owners looking to scale up their business can refer this report that contains data regarding the rise in sales within a given consumer base for the forecast period, 2020 to 2027. Product owners can use this information along with the driving factors such as demographics and revenue generated from other products discussed in the report to get a better analysis of their products and services. Besides, the research analysts have compared the market growth rate with product sales to enable business owners to determine the success or failure of a specific product or service.

By Type

Type 1

Type 2

By Application

Application1

Application 2

Global Stem Cell Alopecia Treatment Market Report 2020 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Stem Cell Alopecia Treatment industry.

The report at a glance

The Stem Cell Alopecia Treatment market report focuses on economic developments and consumer spending trends across different countries for the forecast period 2019 to 2026. The research further reveals which countries and regions will have a better standing in the years to come. Apart from this, the study talks about the growth rate, market share as well as the recent developments in the Stem Cell Alopecia Treatment industry worldwide. Besides, the special mention of major market players adds importance to the overall market study.

Market segment by Region/Country including:

North America (United States, Canada and Mexico) Europe (Germany, UK, France, Italy, Russia and Spain etc.) Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.) South America (Brazil, Argentina, Colombia and Chile etc.) Middle East & Africa (South Africa, Egypt, Nigeria and Saudi Arabia etc.)

The research provides answers to the following key questions:

What is the expected growth rate of the Stem Cell Alopecia Treatment market? What will be the market size for the forecast period, 20202027?

What are the major driving forces responsible for transforming the trajectory of the industry?

Who are major vendors dominating the Stem Cell Alopecia Treatment industry across different regions? What are their winning strategies to stay ahead in the competition?

What are the market trends business owners can rely upon in the coming years?

What are the threats and challenges expected to restrict the progress of the industry across different countries?

What are the key opportunities that business owners can bank on for the forecast period, 20202027?

Why Choose Verified Market Research?

To summarize, the global Stem Cell Alopecia Treatment market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Mr. Edwyne Fernandes

US: +1 (650)-781-4080 UK: +44 (203)-411-9686 APAC: +91 (902)-863-5784 US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Canine Stem Cell Therapy Expansion Projected to Gain an Uptick During 2019-2026 – Jewish Life News

By adminJuly 22, 2020Stem Cell Treatment

Most recent report on the global Canine Stem Cell Therapy market

A recent market study reveals that the global Canine Stem Cell Therapy market is likely to grow at a CAGR of ~XX% over the forecast period (2019-2029) largely driven by factors including, factor 1, factor 2, factor 3, and factor 4. The value of the global Canine Stem Cell Therapy market is estimated to reach ~US$ XX Bn/Mn by the end of 2029 owing to consistent focus on research and development activities in the Canine Stem Cell Therapy field.

Valuable Data included in the report:

Competitive Outlook

The presented business intelligence report includes a SWOT analysis for the leading market players along with vital information including, revenue analysis, market share, pricing strategy of each market players.

Some of the top tier players profiled in the report include:

Product adoption Analysis

A complete assessment of the market share, consumption patterns, and supply-demand ratio of each product is provided backed by insightful tables, figures, and graphs. The products covered in the report include:

The resourceful market study outlines the overall prospects of the Canine Stem Cell Therapy market in the major geographies including region 1, region 2, region 3, and region 4. The most prominent market players, observable trends, opportunities, and challenges in each region is enclosed in the report.

Important Queries Addressed in the report:

Why Our Clients Trust Canine Stem Cell Therapy Market Report?

With a systematic and methodic approach, our analysts collect data from credible primary and secondary sources. In addition, we offer the most efficient after sales services to our customers and address their problems without any delay.

More here:
Canine Stem Cell Therapy Expansion Projected to Gain an Uptick During 2019-2026 - Jewish Life News

Acute Myeloid Leukemia Therapeutics Market To Reach USD 3.56 Billion By 2027 | Reports And Data – GlobeNewswire

By adminJuly 22, 2020Stem Cell Treatment

July 22, 2020 15:04 ET | Source: Reports and Data

New York, July 22, 2020 (GLOBE NEWSWIRE) -- Market Size USD 1.46 Billion in 2019, Market Growth - CAGR of 13.1%, Market Trends Implementing various growth strategies in therapeutics.

New York, July 23, 2020-The GlobalAcute Myeloid Leukemia Therapeutics Marketis forecast to reach USD 3.56 Billion by 2027, according to a new report by Reports and Data. The global acute myeloid leukemia therapeutics market is expected to gain a lucrative increase over the forecast period due to the increasing occurrences of acute myeloid leukemia and its recurrence cases across the globe. Reinforcing the need for forwarding therapeutics is also a high-impact rendering operator of this market. Increasing occurrences of acute myeloid leukemia therapeutics are related to administrators such as genetic variations, unhealthy lifestyles, continued exposure to dangerous chemicals such as benzene, and radiation exposure. Moreover, an increase in the geriatric population base and growing unmet healthcare needs are expected to boost market growth further.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/3354

Limitations in the current drug therapies for acute myeloid leukemia could potentially give rise to the need for improved and effective treatments, also stimulating market growth. The benefits of these therapies include long-term survival rates, increased safety, and enhanced quality. Furthermore, a higher chance of early description of leukemia cells, targeted therapy, and reduced chances of relapse of the acute myeloid leukemia are further supposed to benefit the industry in the forecast period.

COVID-19 Impact:

As the COVID-19 crisis grows, producers are quickly changing their practice & purchasing priorities to meet the required demand of a pandemic. The extensive study of the segments and sub-segments looks at the overall market. Market forecasts will provide in-depth insights into industry parameters by accessing growth, consumption, upcoming market trends, and price fluctuations. The market value will affect a lot due to the higher demand for hospital visits and excessive use of medical supplies.

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/acute-myeloid-leukemia-therapeutics-market

Further key findings from the report suggest

Order Now: https://www.reportsanddata.com/checkout-form/3354

For this report, Reports and Data has segmented the Global Acute Myeloid Leukemia Therapeutics Market based on Regimen, Treatment Type, End-user, and Region:

Regimen Outlook (Revenue, USD Billion; 2017-2027)

Treatment Type Outlook (Revenue, USD Billion; 2017-2027)

End-User Outlook (Revenue, USD Billion; 2017-2027)

Regional Outlook (Revenue, USD Billion; 2017-2027)

Browse more similar reports on Therapeutics category by Reports And Data

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

John W Head of Business Development Reports And Data | Web: http://www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com LinkedIn | Twitter | Blogs

Read the rest here:
Acute Myeloid Leukemia Therapeutics Market To Reach USD 3.56 Billion By 2027 | Reports And Data - GlobeNewswire

Research Roundup: Global methane emissions at all-time high, neuronal pathway prevents relapse, possible drug target to help fight infectious diseases…

By adminJuly 22, 2020Stem Cell Medicine

Our roundup this week highlights research that found global methane emissions have reached an all-time high, with the planet absorbing nearly 600 million tons of methane emissions in 2017. (Photo: Unsplash)

Each week, The Dailys Science & Tech section produces a roundup of the most exciting and influential research happening on campus or otherwise related to Stanford. Heres our digest for the week of July 12 July 18.

Global methane emissions reach an all-time high

The global methane emissions have reached an all-time high, despite carbon dioxide emissions temporarily dropping due to the coronavirus pandemic, a study published on July 14 in Earth System Science Data and Environmental Research Letters found.

We still havent turned the corner on methane, earth system science professor Rob Jackson told Stanford News. Emissions from cattle and other ruminants are almost as large as those from the fossil fuel industry for methane. People joke about burping cows without realizing how big the source really is.

The team analyzed emissions from 2017, the most recent year from which complete global methane data is available, and found that the atmosphere absorbed almost 600 million tons of methane. Methane traps heat more powerfully than carbon dioxide.

The findings suggest agriculture made up two-thirds of methane emissions between 2000 to 2017, with fossil fuel making up the final third.

Well need to eat less meat and reduce emissions associated with cattle and rice farming and replace oil and natural gas in our cars and homes, Jackson told Stanford News. Im optimistic that, in the next five years, well make real progress in that area.

Neuronal pathway prevents drug relapse in mice

Disrupting a neuronal pathway that causes opiate-associated memories in mice prevents drug relapse and has the potential to treat opioid addiction in patients, a study published on July 16 in Neuron found.

The most difficult part of treating addiction is to prevent relapse, especially for opioids, biology associate professor Xiaoke Chen told Stanford News. To prevent relapse, we really need to deal with the withdrawal.

The findings suggest when the researchers silenced the paraventricular thalamus in morphine-dependent mice, the mice no longer preferentially chose morphine over the drug-free saline solution. Through disrupting this neural pathway, researchers found that the animals had no memory of the effects of the drug. Paraventricular thalamus is a brain region that connects many different brain areas associated with drug addiction.

Drugs as a stimulus can drive a very robust behavior, Chen told Stanford News. I want to understand the mechanism underlying that behavior and hope that this knowledge can help address the devastating opioid epidemic in the U.S.

Molecular signal, a possible drug target, allows virus-infected cells to evade immune system

Blocking CD47, a molecular signal, in virus-infected cells allows the immune system to target infected cells, a study published on June 23 in mBio found. Decreasing CD47 may help the body fight infectious disease, serving as a potential drug target.

Cancer cells also increase their CD47 signaling to evade immune system attack.

We wondered whether the mechanism activated by all cancer cells to avoid being destroyed could also be used by persistent infections, so that the microbes can hide inside cells to evade immune cells, pathology stem cell and developmental biology professor Irving Weissman M.D. 65 told Stanford Medicine News. Amazingly, we found that to be true, and blocking the CD47 signal helped the body get rid of more infected cells.

The findings suggest mice and humans cells infected by pathogens show increased expression of the CD47 molecular signal. Additionally, the team found that mice without the gene for CD47 were more resistant to tuberculosis-causing bacteria than control mice.

Infected cells with SARS-CoV-2 the virus that causes COVID-19 also produce increased CD47 signaling, so treatments that block CD47 production could potentially be used in coronavirus patients.

Its probably important for the innate immune system to have a balance of activating and suppressing forces, but we showed that if we play with that balance a little bit, we can clear some pathogens faster, Michal Tal, an instructor at the Institute for Stem Cell Biology and Regenerative Medicine, told Stanford Medicine News. In some cases, it might be better to ease up on this particular immunological brake by blocking CD47.

Contact Derek Chen at derekc8 at stanford.edu.

More:
Research Roundup: Global methane emissions at all-time high, neuronal pathway prevents relapse, possible drug target to help fight infectious diseases...

Data Shows Direct Link Between COVID-19 and Acute Respiratory Distress Syndrome (ARDS) In Infected P – PharmiWeb.com

By adminJuly 22, 2020Adult Stem Cells

PALM BEACH, Fla., July 22, 2020 /PRNewswire/ -- There is a direct link between the COVID-19 virus and acute respiratory distress syndrome (ARDS) in COVID-19 patients. According to the National Institutes of Health about 80% of COVID-19 infections are mild or asymptomatic and never require hospitalization but about 5% of patients become critically ill anddevelop acute respiratory distress syndrome. An article from Johns Hopkins Medical adds that COVID-19, can cause lung complications such as pneumoniaand, in the most severe cases, acute respiratory distress syndrome As COVID-19 pneumonia progresses, more of the air sacs become filled with fluid leaking from the tiny blood vessels in the lungs. Eventually, shortness of breath sets in, and can lead to acute respiratory distress syndrome, a form of lung failure. COVID-19 patients with ARDS are often unable to breath on their own and may require ventilator support to help circulate oxygen in the body. Active healthcare stocks in news today include: Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), Moderna, Inc., (NASDAQ: MRNA), Oragenics, Inc. (NYSE: OGEN), Pfizer Inc. (NYSE: PFE), Dynavax Technologies Corporation (NASDAQ: DVAX).

Another report from ReportsAndData addresses the result of this association on ARDS revenues. They said: "The global acute respiratory distress syndrome (ARDS) market is expected to reach USD 934.8 Million by the year 2026, at a CAGR of 6.0%. Acute respiratory distress syndrome (ARDS) is a respiratory disease wherein the lungs cannot adequately deliver oxygen to the vital body organs. In Acute respiratory distress syndrome (ARDS), fluid gets accumulated in tiny elastic air sacs called alveoli and creates blockade for the lungs to breathe air oxygen is not adequately delivered to the body organs, which can affect their proper functioning. Rising R&D activities by local companies and education institutes to develop advanced and effective treatment methods for ARDS can augment regional market growth."

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)BREAKING NEWS - Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19 - Citius Pharmaceuticals ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today the formation of the Citius ARDS (Acute Respiratory Distress Syndrome) Scientific Advisory Board to provide the company expert guidance on its planned development of induced mesenchymal stem cells (iMSCs) under option from Novellus, Inc. to treat and reduce the severity of acute respiratory distress syndrome (ARDS) associated with COVID -19.

The ARDS Advisory Board consultants are:

Michael A. Matthay, MD, Professor of Medicine and Anesthesia at the University of California at San Francisco (UCSF), a Senior Associate at the Cardiovascular Research Institute, and Associate Director of the Critical Care Medicine at UCSF. Dr. Matthay's basic research has focused on the pathogenesis and resolution of the acute respiratory distress syndrome (ARDS), with an emphasis on translational work and patient-based research, including clinical trials. Dr. Matthay's recent research has focused on the biology and potential clinical use of allogeneic bone marrow derived mesenchymal stromal cells (MSCs) for ARDS. He is currently leading the "Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (STAT)," a United States Department of Defense supported study of MSCs for ARDS.

Mitchell M. Levy, MD, Chief, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, The Warren Alpert Medical School of Brown University, where he is Professor of Medicine.Dr. Levy also serves as Medical Director of the Medical ICU at Rhode Island Hospital. He has been an investigator on numerous pharmacologic and biologic trials intended to treat sepsis, cardiovascular and pulmonary pathology. He has expertise in trial design, clinical trial execution and trial management and is one of the three founding members of the Surviving Sepsis Campaign (SSC). Dr. Levy is Past-President of the Society of Critical Care Medicine (2009).

Lorraine B. Ware, MD, Professor of Medicine and Ralph and Lulu Owen Endowed Chair, Professor of Pathology, Microbiology and Immunology, Vanderbilt University; Director, Vanderbilt Medical Scholars Program. Dr. Lorraine Ware's comprehensive bench-to-bedside research program centers on the pathogenesis and treatment of sepsis and acute lung injury with a current focus on mechanisms of lung epithelial and endothelial oxidative injury by cell-free hemoglobin. Dr. Ware is also a lead investigator for the "Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (STAT)" study.

"We are extremely pleased to have been able to attract such a prestigious group of experts to advise and guide us in the Company's planned development of iMSC's for the treatment of ARDS" said Mr. Myron Holubiak, CEO of Citius. "These individuals are recognized opinion leaders and expert in the planning and execution of clinical trials in this therapeutic area. We will be seeking their advice in all phases of our clinical trial design."Read this full release at: https://ir.citiuspharma.com/press-releases/detail/109/citius-pharmaceuticals-forms-scientific-advisory-board-for

In other healthcare news of note:

Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Icahn School of Medicine at Mount Sinai ("Mount Sinai") announced they have entered into a collaboration to develop a universal influenza (flu) vaccine. Mount Sinai's current work in this area is funded under a contract award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), as part of the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program established by NIAID.The Mount Sinai CIVICs team will evaluate a novel approach they have developed called chimeric hemagglutinin (cHA) designed to protect against all strains of influenza in combination with Dynavax's CpG 1018TM adjuvant.

The development program will support an Investigational New Drug (IND) application for Phase I clinical trials. Drs. Peter Palese, PhD, Professor and Chair of the Department of Microbiology at Mount Sinai, Adolfo-Garcia-Sastre, PhD, Director of the Global Health and Emerging Pathogens Institute, and the Irene and Dr. Arthur M. Fishberg Professor of Microbiology and Medicine (Infectious Diseases) at Mount Sinai, and Florian Krammer, PhD, Professor of Microbiology at Mount Sinai will be leading the development of the program.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government's Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. Under the agreement, the U.S. government will receive 100 million doses of BNT162, the COVID-19 vaccine candidate jointly developed by Pfizer and BioNTech, after Pfizer successfully manufactures and obtains approval or emergency use authorization from U.S. Food and Drug Administration (FDA).

Oragenics, Inc. (NYSE American: OGEN) announced that the National Institutes of Health (the "NIH") created stabilized pre-fusion spike protein (CoV-2 S-2P) licensed by the Company has generated neutralizing antibodies in mice during immunization against SARS-CoV-2, the virus that causes COVID-19.

The NIH's preclinical study shows that this spike protein, adjuvanted with the TLR-4-agonist Sigma Adjuvant System (a TLR-4 agonists that induces T cell activation), generates neutralizing antibody titers in both a pseudovirus neutralization assay and a plaque reduction neutralization titer (PRNT) assay. In addition, this immunization produced a balanced Th1/Th2 response. The results are reported in Corbett et al. BioRxiv. 2020

Moderna, Inc., (NASDAQ: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, recently announced the publication of an interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in The New England Journal of Medicine. This interim analysis evaluated a two-dose vaccination schedule of mRNA-1273 given 28 days apart across three dose levels (25, 100, 250 g) in 45 healthy adult participants ages 18-55 years, and reports results through Day 57. Results from participants in the initial dose cohorts who received both vaccinations and were evaluated at pre-specified timepoints reaffirm the positive interim data assessment announced on May 18th and show mRNA-1273 induced rapid and strong immune responses against SARS-CoV-2. The study was led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.FNM is NOT affiliated in any manner with any company mentioned herein.FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.FNM is not liable for any investment decisions by its readers or subscribers.Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.For current services performed FNM was compensated forty five hundred dollars for news coverage of the current press releases issued by Citius Pharmaceuticals, Inc. by a non affiliated third party.FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email:editor@financialnewsmedia.com +1(561)325-8757

View original content:http://www.prnewswire.com/news-releases/data-shows-direct-link-between-covid-19-and-acute-respiratory-distress-syndrome-ards-in-infected-patients-301098259.html

SOURCE Financialnewsmedia.com

See the article here:
Data Shows Direct Link Between COVID-19 and Acute Respiratory Distress Syndrome (ARDS) In Infected P - PharmiWeb.com

Potential Risks of Treatment with Unapproved Regenerative Medicine Products – FDA.gov

By adminJuly 22, 2020Stem Cell Clinic

By: Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research

Protecting patients is at the core of what we do at the U.S. Food and Drug Administration. Now the FDA is providing additional resources to help consumers understand the risks associated with unapproved stem cell, exosome, and other products marketed as regenerative medicine products. The agency is also facilitating the reporting of side effects that may occur after their use. The FDAs receipt of this information is important to developing a better understanding of the risks associated with these products and to helping the agency identify those clinics and manufacturers putting patients at risk.

Several times in recent years, the FDA warned consumers who have been treated with, or who are considering use of, unapproved stem cell, exosome, or other products marketed as regenerative medicine products, about their potential risk. These illegal products are often marketed by clinics under the umbrella term of regenerative medicine as being safe and effective for treatment of a wide range of diseases or conditions (e.g., Alzheimers disease and other neurologic disorders, orthopedic conditions), even though they have not been adequately studied in clinical trials. And more recently, some of these clinics have been marketing or distributing their unproven products to treat complications related to COVID-19 claims that are not based on adequate clinical data.

Consumers may also have been told by clinics and health care providers that because some of these products are made from their own cells, the FDA does not need to review or approve the treatment. That is simply not true. Further, claims that a clinics FDA registration or inspection equates to FDA approval or a form of FDA endorsement, or that listing a clinical study on clinicaltrials.gov means that it has been reviewed and allowed to proceed by the FDA, are also false.

It is of utmost concern that unapproved regenerative medicine products that have no proven clinical benefit and that may cause serious harm are marketed to patients. Using these products may lead to delays in getting a proper diagnosis and could also discourage patients suffering from serious illnesses from receiving safe and effective treatments that may be available. Whats also concerning is that we know that because these products are not FDA-approved, its very likely that adverse events are underreported by health care providers who treat patients with these products, and by patients who may have been harmed. We therefore strongly encourage patients and their family members to ask questions before receiving these types of products has the product been approved by the FDA? Has the product been approved for this use? Is the product being studied in a clinical trial that has been reviewed and allowed to proceed by the FDA? Am I being charged for an unapproved product?

We encourage patients and their health care providers to report to the FDA any potential adverse events and complaints related to the use of these products using the FDAs MedWatch Adverse Event Reporting program. Stem cell, exosome, or other products marketed as regenerative medicine products may have the potential to treat many medical conditions and diseases. But for almost all these products, it is not yet known whether each product has any benefit or if the product is safe to use. We want to make sure patients understand these potential risks in order to protect themselves from being treated with and paying for an unproven and illegally marketed products. The FDA has posted a webpage for consumers that provides information about products marketed as stem cells, exosomes or other regenerative medicine products, including the conditions for which they are approved, and which products are not approved at all. The webpage also provides information on how to submit information about adverse events to the FDAs MedWatch Adverse Event Reporting Program.

Unfortunately, weve found numerous instances of products being marketed to patients without FDA approval, as well as products being manufactured with significant deviations from current good tissue practice (CGTP) and/or current good manufacturing practice (CGMP) requirements. These violations have included deficient donor eligibility practices, and inadequate aseptic practices to prevent product contamination violations that have the potential to place patients at risk. Patients have been harmed after being administered some of these violative products.

We encourage consumers who are considering treatment with regenerative medicine products to work with their health care providers to learn about the treatment being offered, and to visit our webpage. It is important to ask questions and understand the potential risks of treatment with unapproved products. The FDA will continue to work with the manufacturers of these products to support their development. But we will also continue to take appropriate action against those who put patients in harms way.

Additional Resources:

Here is the original post:
Potential Risks of Treatment with Unapproved Regenerative Medicine Products - FDA.gov

GV’s David Schenkein comes in to help mentor and bankroll a gene therapy 2.0 player, intrigued by their ‘science heavy’ approach to conquering…

By adminJuly 22, 2020Stem Cell Clinic

One of the leading programs for a new coronavirus vaccine was championed today as investigators from Oxford and AstraZeneca spelled out a dual hit with neutralizing antibodies as well as a surge in specific T cells targeted against the virus.

According to the study:

Humoral responses to SARS-CoV-2 spike protein peaked by day 28 postprime and cellular responses were induced in all participants byday 14. Neutralising antibodies were induced in all participants after a second vaccine dose. After two doses, potent cellular and humoral immunogenicity was present in all participants studied.

The results largely confirm what was already previewed: One dose was sufficient to elicit some antibody response in over 90% of people, and a second dose pushed it to 100%, at levels similar to whats observed in convalescent patients. Spike-specific effectors T cells were observed as early as day 7, peaking at day 14 and maintained up to day 56 as expected with adenoviral vectors.

In a media briefing, AstraZeneca biopharma R&D head Mene Pangalos noted that the ongoing Phase III trials will almost certainly be testing two doses, as it would be the safest approach to making sure we hit efficacy. Lower doses can then be worked out in the future.

Unlock this story instantly and join 85,500+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Continue reading here:
GV's David Schenkein comes in to help mentor and bankroll a gene therapy 2.0 player, intrigued by their 'science heavy' approach to conquering...